AbbVie Inc. (ABBV) Stock Analysis
AbbVie Inc. (ABBV) is a research-based biopharmaceutical company that develops and commercializes medicines across immunology, oncology, aesthetics, and neurology. Investors research ABBV for its diversified drug portfolio, strong cash generation, and exposure to high-growth therapeutic areas like autoimmune and cancer treatments.
Get a full AI research report on ABBV
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does AbbVie Inc. do?
AbbVie generates revenue through the discovery, development, manufacturing, and sale of prescription pharmaceuticals and specialty medicines worldwide. The company's portfolio includes blockbuster drugs like Skyrizi (autoimmune), Rinvoq (inflammatory), Imbruvica (blood cancers), and Botox (both therapeutic and cosmetic applications). Revenue is supplemented by facial injectables and regenerative medicine products, creating a diversified income stream across multiple therapeutic categories and geographies.
Bull case
- ✓Forward P/E ratio of 15.23 suggests the stock is priced at a discount to its near-term earnings growth expectations, compared to the trailing P/E of 122.21 which reflects a recent earnings trough or one-time items.
- ✓Gross margin of 72% demonstrates strong pricing power and manufacturing efficiency, allowing the company to retain substantial capital for R&D and shareholder returns.
- ✓PEG ratio of 0.4 indicates the stock may be trading below its expected earnings growth rate, a metric some value investors monitor for undervaluation.
- ✓Operating margin of 32% shows the company converts a significant portion of revenue into operating profit, reflecting operational leverage and successful cost management.
- ✓Dividend yield of 2.79% provides current income to shareholders, with the company maintaining a dividend despite a high payout ratio, signaling confidence in cash flow stability.
Bear case
- ✗Current ratio of 0.796 and quick ratio of 0.519 indicate potential short-term liquidity constraints, as current liabilities exceed current assets by a meaningful margin.
- ✗Trailing P/E of 122.21 is extremely elevated, suggesting either depressed recent earnings, significant one-time charges, or market expectations of substantial near-term recovery that may not materialize.
- ✗Payout ratio of 326% is unsustainable, indicating the company is returning more cash to shareholders than it generates in net income, relying on debt or asset sales to fund dividends.
- ✗EV/EBITDA of 16.78x is elevated for a mature pharmaceutical company, implying the market has priced in significant future growth or margin expansion.
- ✗Patent cliffs and generic competition pose ongoing risks to blockbuster drugs, requiring continuous innovation and successful commercialization of pipeline candidates to maintain revenue.
ABBV valuation & financial health
AbbVie's valuation presents a mixed picture: the forward P/E of 15.23 and PEG of 0.4 suggest reasonable pricing relative to expected growth, but the trailing P/E of 122.21 reflects distorted recent earnings. Profitability metrics are strong—gross margin of 72% and operating margin of 32% demonstrate pricing power and operational efficiency—while net margin of 5.79% shows earnings are compressed after interest and taxes. However, liquidity is a concern: the current ratio of 0.796 and quick ratio of 0.519 indicate the company carries more short-term obligations than liquid assets, and a payout ratio exceeding 300% is unsustainable without debt financing. Return on assets of 10% is modest for a pharmaceutical company, suggesting capital is not generating outsized returns. The company's ability to service its dividend and fund operations depends on continued strong cash generation and access to capital markets.
The bottom line
AbbVie presents a complex investment profile that requires careful analysis of forward versus trailing metrics. The forward P/E and PEG ratio suggest the market has priced in a recovery from depressed recent earnings, while the strong gross and operating margins reflect the underlying business quality. Key factors to weigh include the sustainability of the dividend given the unsustainable payout ratio, the company's ability to navigate patent expirations and maintain market share in key franchises like Skyrizi and Rinvoq, and whether near-term liquidity constraints signal operational stress or simply reflect timing of debt maturities. Investors should monitor upcoming earnings reports, pipeline progress on new drug candidates, and management commentary on cash flow and capital allocation priorities.
Frequently asked questions
What does AbbVie Inc. do?
AbbVie is a biopharmaceutical company that researches, develops, manufactures, and sells prescription medicines and therapies. Its portfolio spans immunology, oncology, aesthetics, and neurology, including well-known brands like Skyrizi, Botox, Rinvoq, and Imbruvica.
Is ABBV overvalued or undervalued?
Valuation depends on which metric you examine: the forward P/E of 15.23 and PEG of 0.4 suggest reasonable pricing, while the trailing P/E of 122.21 is distorted by recent earnings weakness. The EV/EBITDA of 16.78x is elevated for the sector, requiring confidence in future growth to justify the price.
What are AbbVie's main revenue drivers?
Primary revenue comes from blockbuster drugs Skyrizi (autoimmune diseases), Rinvoq (inflammatory conditions), Imbruvica (blood cancers), and Botox (therapeutic and cosmetic uses). The company also generates revenue from facial injectables, regenerative medicine, and a diversified pipeline of oncology and neurology products.
Is ABBV financially healthy?
AbbVie demonstrates strong profitability with 72% gross margin and 32% operating margin, but liquidity is tight with a current ratio of 0.796. The payout ratio exceeding 300% is unsustainable without debt financing, raising questions about the long-term sustainability of the dividend at current levels.
What risks should investors monitor?
Key risks include patent cliffs on major drugs, generic competition, the unsustainable dividend payout ratio, tight short-term liquidity, and the company's dependence on successful commercialization of pipeline candidates to offset revenue losses from aging franchises.
Does AbbVie pay a dividend?
Yes, AbbVie pays a dividend with a yield of 2.79%, providing current income to shareholders. However, the payout ratio of 326% indicates the company is returning significantly more cash than it earns, which is not sustainable long-term without changes to the dividend or improved earnings.
Research ABBV with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.